4521 On Other Exchanges
Symbol
Exchange
4521 is not on other exchanges.

kaken pharmaceutical co ltd (4521) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAKEN PHARMACEUTICAL CO LTD (4521)

Related News

No related news articles were found.

kaken pharmaceutical co ltd (4521) Related Businessweek News

No Related Businessweek News Found

kaken pharmaceutical co ltd (4521) Details

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. It operates through two segments, Pharmaceuticals and Real Estate. The company offers pharmaceutical and medical devices products, such as Artz, an anti-osteoarthritis drug to treat knee joint pain accompanied by rheumatoid arthritis; Clenafin, a triazole compound for topical medication for onychomycosis; Seprafilm, an anti-adhesive absorbent barrier; Lipidil, an anti-hyperlipidemia product; and Fiblast Spray, a wound-healing drug. Its pharmaceutical and medical devices products also include Procylin, which is used to treat chronic artery occlusive diseases and pulmonary hypertension; Adofeed, a pain- and inflammation-relieving plaster; Mentax, a topical product used to treat superficial mycosis; Ebrantil, a a1 blocker to treat dysuria and hypertension; Berasus to treat pulmonary arterial hypertension; and Clexane, an anticoagulant for the treatment of patients who undergo podiatric or abdominal surgery. In addition, the company provides agrochemicals, including Polyoxins that is used as fungicide; and Pentoxazone, a rice herbicide. Further, it offers animal health products comprising Salinomycin, an anti-coccidial feed additive for chicken; and Colistin sulfate, a polypeptide antibiotic effective against gram-negative bacteria. Additionally, the company is developing KCB-1D for the treatment of periodontitis; KAG-308, a Phase II clinical product to treat Ulcerative colitis; BBI-4000 that is in pre-clinical stage to treat primary focal hyperhidrosis; and SI-657, which is in Phase-III clinical trials to treat Enthesopathy. It primarily focuses on fields, such as inflammation, allergies, and pain relief, as well as fungal infection. The company also rents Bunkyo Green Court commercial facility. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

1,451 Employees
Last Reported Date: 06/29/16
Founded in 1917

kaken pharmaceutical co ltd (4521) Top Compensated Officers

President and Representative Director
Total Annual Compensation: ¥110.0M
Compensation as of Fiscal Year 2016.

kaken pharmaceutical co ltd (4521) Key Developments

Kaken Pharmaceutical Co. Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2016; Provides Earnings and Dividend Guidance for the Six Months and Full Year of Fiscal Year 2017

Kaken Pharmaceutical Co. Ltd. reported consolidated earnings results for the first quarter ended June 30, 2016. For the quarter, the company reported income before income taxes of JPY 8,187 million against JPY 9,346 million a year ago. For the six months of fiscal year 2017, the company expects net sales of JPY 52,700 million, operating income of JPY 14,100 million, ordinary income of JPY 14,200 million and net income attributable to owners of parent was JPY 10,000 million or JPY 243.16 per share. For the fiscal year 2017, the company expects net income attributable to owners of parent per share of JPY 505.78. The company provides second quarter and year end dividend guidance for the fiscal year 2017. The company expects to pay second quarter and year end dividend of JPY 75 per share.

Kaken Pharmaceutical Co. Ltd. Reports Consolidated Earnings Results for the First Quarter of 2016; Provides Earnings Guidance for the Fiscal Year 2016

Kaken Pharmaceutical Co. Ltd. reported consolidated earnings results for the first quarter of 2016. For the quarter, the company reported net sales of JPY 26,228 million, operating income of JPY 8,097 million, ordinary income of JPY 8,217 million and net income of JPY 5,796 million compared to net sales of JPY 27,633 million, operating income of JPY 9,234 million, ordinary income of JPY 9,362 million and net income of JPY 6,300 million a year ago. For the fiscal year 2016, the company expects net sales of JPY 106,100 million, operating income of JPY 28,900 million, ordinary income of JPY 29,100 million and net income of JPY 20,800 million.

Kaken Pharmaceutical Co. Ltd. to Report Q1, 2017 Results on Aug 03, 2016

Kaken Pharmaceutical Co. Ltd. announced that they will report Q1, 2017 results on Aug 03, 2016

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4521 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4521.
View Industry Companies
 

Industry Analysis

4521

Industry Average

Valuation 4521 Industry Range
Price/Earnings 13.3x
Price/Sales 2.5x
Price/Book 3.0x
Price/Cash Flow 15.3x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KAKEN PHARMACEUTICAL CO LTD, please visit www.kaken.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.